357 related articles for article (PubMed ID: 32687498)
1. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
Goyal V; Das VNR; Singh SN; Singh RS; Pandey K; Verma N; Hightower A; Rijal S; Das P; Alvar J; Bern C; Alves F
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008429. PubMed ID: 32687498
[TBL] [Abstract][Full Text] [Related]
2. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
[TBL] [Abstract][Full Text] [Related]
3. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.
Goyal V; Mahajan R; Pandey K; Singh SN; Singh RS; Strub-Wourgaft N; Alves F; Rabi Das VN; Topno RK; Sharma B; Balasegaram M; Bern C; Hightower A; Rijal S; Ellis S; Sunyoto T; Burza S; Lima N; Das P; Alvar J
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006830. PubMed ID: 30346949
[TBL] [Abstract][Full Text] [Related]
4. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
Mondal D; Kumar A; Sharma A; Ahmed MM; Hasnain MG; Alim A; Huda MM; Rahman R; Alvar J; Ahmed BN; Haque R
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
[TBL] [Abstract][Full Text] [Related]
5. Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India.
Goyal V; Burza S; Pandey K; Singh SN; Singh RS; Strub-Wourgaft N; Das VNR; Bern C; Hightower A; Rijal S; Sunyoto T; Alves F; Lima N; Das P; Alvar J
PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007726. PubMed ID: 31557162
[TBL] [Abstract][Full Text] [Related]
6. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
7. Antimony susceptible
Ghosh S; Verma A; Kumar D; Deep DK; Ramesh V; Salotra P; Singh R
Microbiol Spectr; 2024 Jun; 12(6):e0402623. PubMed ID: 38712926
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
9. Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Lima MA; Mitra G; Verma N; Balasegaram M; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2603. PubMed ID: 24392168
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India.
Das VN; Pandey RN; Siddiqui NA; Chapman LA; Kumar V; Pandey K; Matlashewski G; Das P
PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005196. PubMed ID: 27974858
[TBL] [Abstract][Full Text] [Related]
11. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
12. Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India.
Das VN; Ranjan A; Pandey K; Singh D; Verma N; Das S; Lal CS; Sinha NK; Verma RB; Siddiqui NA; Das P
Am J Trop Med Hyg; 2012 Jun; 86(6):959-61. PubMed ID: 22665600
[TBL] [Abstract][Full Text] [Related]
13. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
[TBL] [Abstract][Full Text] [Related]
14. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
[TBL] [Abstract][Full Text] [Related]
15. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study.
Das S; Mandal R; Rabidas VN; Verma N; Pandey K; Ghosh AK; Kesari S; Kumar A; Purkait B; Lal CS; Das P
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005060. PubMed ID: 27776123
[TBL] [Abstract][Full Text] [Related]
16. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
17. Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.
Pandey K; Das VN; Singh D; Das S; Lal CS; Verma N; Bimal S; Topno RK; Siddiqui NA; Verma RB; Sinha PK; Das P
J Clin Microbiol; 2012 Apr; 50(4):1478-9. PubMed ID: 22278840
[TBL] [Abstract][Full Text] [Related]
18. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
[TBL] [Abstract][Full Text] [Related]
19. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
20. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
